SAMD4B and breast carcinoma: To confirm whether SAMD4B promotes the growth and metastasis of breast cancer cells by directly activating the Wnt/β-catenin pathway, we treated SAMD4B-overexpressing breast cancer cells with XAV-939, a specific inhibitor of the Wnt/β-catenin pathway and systematically evaluated the regulatory effects of this intervention on breast cancer cell proliferation and metastatic potential.